MedPath

Prevention of bleeding after bronchoscopic biopsy with the use of prophylactic local tranexemic acid

Not Applicable
Conditions
Health Condition 1: J980- Diseases of bronchus, not elsewhere classified
Registration Number
CTRI/2023/05/052223
Lead Sponsor
Pulmonary Medicine Department of AIIMS Jodhpur
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age > 18 years

2.All patients requiring EBB or TBLB and fulfilling the fitness to undergo flexible bronchoscopy.

3.Patients providing prior written informed consent

Exclusion Criteria

1.Coagulopathy: INR >1.5

2.Thrombocytopenia: platelets count < 50000

3.Anaemia: haemoglobin < 7gm/dl

4.Ongoing treatment with direct oral anticoagulant agents (DOAC), low molecular weight heparin (LMWH) or dual antiplatelet therapy (DAPT)

5. Patients with unstable or recent coronary heart disease or cerebrovascular disease

6.Decompensated liver disease, end stage kidney disease

7.Uncontrolled arrhythmia.

8.Hemodynamic instability and cardiovascular decompensation: patients with hypotension (MAP <65mm of hg)

9.Severe hypoxemia prior to bronchoscopy start (PaO2 <60mmog hg and Spo2 <90% with Fio2 of 60% or higher)

10.Refusal to consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of prophylactic topical instillation of TXA with cold saline for prevention or reduction of bleeding after endobronchial or transbronchial forceps biopsy during flexible bronchoscopy.Timepoint: 6 months, 12 months, 18 months
Secondary Outcome Measures
NameTimeMethod
1.The number of biopsies obtained <br/ ><br>2.Need of additional measures (cold saline, ADR, Balloon tamponade) to achieve haemostasis in case of uncontrolled bleeding. <br/ ><br>3.Assess the adverse effect of TXA. <br/ ><br>Timepoint: 6 months, 12 months, 18 months
© Copyright 2025. All Rights Reserved by MedPath